Compare PRVA & RLAY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | PRVA | RLAY |
|---|---|---|
| Founded | 2007 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Retail: Computer Software & Peripheral Equipment | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.5B | 4.1B |
| IPO Year | 2021 | 2020 |
| Metric | PRVA | RLAY |
|---|---|---|
| Price | $27.79 | $18.97 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 12 | 10 |
| Target Price | ★ $31.17 | $19.50 |
| AVG Volume (30 Days) | 1.2M | ★ 4.2M |
| Earning Date | 05-07-2026 | 05-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 63.64 | 31.78 |
| EPS | ★ 0.02 | N/A |
| Revenue | ★ $2,122,842,000.00 | $15,355,000.00 |
| Revenue This Year | $18.19 | N/A |
| Revenue Next Year | $10.72 | $324.03 |
| P/E Ratio | $1,396.45 | ★ N/A |
| Revenue Growth | 22.26 | ★ 53.44 |
| 52 Week Low | $18.78 | $3.03 |
| 52 Week High | $28.41 | $20.79 |
| Indicator | PRVA | RLAY |
|---|---|---|
| Relative Strength Index (RSI) | 71.33 | 57.03 |
| Support Level | $22.78 | $12.10 |
| Resistance Level | N/A | $20.79 |
| Average True Range (ATR) | 0.82 | 1.29 |
| MACD | 0.08 | -0.13 |
| Stochastic Oscillator | 72.51 | 41.64 |
Privia Health Group Inc is one of the physician enablement companies in the United States with a presence in around 24 states and the District of Columbia. The group builds scaled provider networks with primary-care centric medical groups, risk-bearing entities, a physician-led governance structure, and the Privia Platform comprising an extensive suite of technology and service solutions. It collaborates with medical groups, health plans, and health systems to optimize approximately 1,300+ physician practices, improve the patient experience for over 5.8+ million patients, and reward around 5,300+ physicians and practitioners for delivering high-value care.
Relay Therapeutics Inc is a clinical-stage precision medicine company transforming the drug discovery process and bringing life-changing therapies to patients. The Dynamo platform of the company integrates an array of leading-edge computational and experimental approaches designed to drug-protein targets that have previously been intractable or inadequately addressed. The company is advancing a pipeline of medicine candidates to address targets in precision oncology and genetic disease, including product candidates, RLY-8186, RLY-2608, RLY-4008 and others.